NFX

Nuformix continues to advance and exploit current assets within the portfolio

Nuformix plc (LON:NFX) announces unaudited results for the six months ended 31 March 2024, highlighting progress in drug repurposing for fibrosis and oncology...

June 18, 2024

Nuformix updates on patents grants for NXP002 & NXP004

Nuformix plc (LON:NFX) announces patent updates for NXP002 and NXP004, highlighting advancements in IPF treatment and cocrystal development...

June 17, 2024

Nuformix to raise £150,000 for NXP002 programme

Nuformix plc (LON:NFX) to raise £150,000 through a subscription for 75,000,000 new ordinary shares to fund the NXP002 programme for idiopathic pulmonary fibrosis...

March 1, 2024

Nuformix plc Innovative Drug Repurposing with Breakthroughs in Fibrosis and Oncology

January 3, 2024

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

December 18, 2023

Nuformix plc Official Decision to Grant from the Japanese Patent Office

October 23, 2023

Nuformix now focusing on out-licencing NXP002 & NXP004 (LON:NFX)

September 28, 2023

Nuformix excited as it moves focus to NXP002 and NXP004 programmes

September 19, 2023

Nuformix receives new NXP001 development milestone payments in updated Oxilio agreement

September 18, 2023

Nuformix hosting online Q&A session on 13 June 2023

June 2, 2023

Nuformix plc has a complete pre-clinical story for potential licensing partners (VIDEO)

May 22, 2023

Nuformix to raise £70,000 for support the overall progression of the NXP002 programme

April 17, 2023

Nuformix “tranilast at the heart of NXP002” in treating fibrosis (LON:NXF)

April 12, 2023

Nuformix NXP002 meets best case scenario objectives (VIDEO)

March 29, 2023

Nuformix plc delighted with NXP002 study results

March 27, 2023

Nuformix further evaluating NXP002 combination therapies now underway

February 15, 2023

Nuformix delighted with NXP004 results which exceeded expectations

December 20, 2022

Nuformix excited by prospects for the remainder of the year

December 13, 2022

Nuformix investor webinar Wednesday 9th November 2022

November 4, 2022

Nuformix lead programme introduced to major respiratory players (VIDEO)

September 23, 2022

News and Interview Alerts

Company Presentations

Time Finance Profits Surge, Book Grows 86% as New Strategy Targets £300m Lending

Challenger Energy plc Transforming Exploration Potential into a Frontier Opportunity

Q&As

Ruffer Investment Company: Defensive strategy and positioning for volatile markets (LON:RICA)

27 January 2026

Finseta CEO on FY2025 revenue growth, Dubai success & platform innovations (LON:FIN)

26 January 2026

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

23 January 2026

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Time Finance Delivers Positive Interim Results, Signals Confidence for Future Growth – Cavendish

28 January 2026

Global Opportunities Trust: Cash builds as valuations rise | New Research

28 January 2026

Record plc Reports Strong Momentum and Record AUM – Panmure Liberum

27 January 2026

The Artisanal Spirits Company Sees Stabilisation and Growth Potential, Says Panmure Liberum

26 January 2026

Record Reports Strong Q3 Growth Driven by Net Flows and Asset Gains – Edison Investment Research

23 January 2026

Funds

ACG Metals positioned for strong cash generation and long-term value as copper production ramps up, highlights DIVI fund manager

6 February 2026

BlueNord ASA fund manager expects very substantial cash generation for years

6 February 2026

Primary Health Properties surplus cash fuels generous dividend, Gervais Williams impressed

4 February 2026

Arbuthnot Banking Group ‘remarkably low valuation given its prospects’ says DIVI Fund Manager

4 February 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Workspace Group PLC (WKP.L) Investor Outlook: What the 14.29% Potential Upside Means for You

6 February 2026

Zigup Plc (ZIG.L) Stock Analysis: Industrial Rental Services Giant with a 30% Upside Potential

6 February 2026

WH Smith PLC (SMWH.L) Investor Outlook: Navigating Potential Upside Amidst Market Challenges

6 February 2026

XPS Pensions Group PLC (XPS.L): Analyst Consensus Points to 29% Upside Potential for UK-Based Pension Specialist

6 February 2026

WORLDWIDE HEALTHCARE TRUST PLC (WWH.L) Stock Analysis: A Look at Recent Price Movements Amidst Strong Buy Ratings

6 February 2026

May 10, 2024

Nuformix continues to advance and exploit current assets within the portfolio

Nuformix plc (LON:NFX) announces unaudited results for the six months ended 31 March 2024, highlighting progress in drug repurposing for fibrosis and oncology...

June 18, 2024

Nuformix updates on patents grants for NXP002 & NXP004

Nuformix plc (LON:NFX) announces patent updates for NXP002 and NXP004, highlighting advancements in IPF treatment and cocrystal development...

June 17, 2024

Nuformix to raise £150,000 for NXP002 programme

Nuformix plc (LON:NFX) to raise £150,000 through a subscription for 75,000,000 new ordinary shares to fund the NXP002 programme for idiopathic pulmonary fibrosis...